Ignite Creation Date:
2024-05-06 @ 10:26 AM
Last Modification Date:
2024-10-26 @ 12:30 PM
Study NCT ID:
NCT03256136
Status:
COMPLETED
Last Update Posted:
2020-11-04
First Post:
2017-08-17
Brief Title:
Nivolumab in Combination With Chemotherapy or Nivolumab in Combination With Ipilimumab in Advanced EGFR-Mutant or ALK-Rearranged NSCLC
Sponsor:
Massachusetts General Hospital
Organization:
Massachusetts General Hospital
Organization Data
Organization:
Massachusetts General Hospital
Class:
OTHER
Study ID:
17-011
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Massachusetts General Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Alice Shaw
Responsible Party Title:
Director Center for Thoracic Cancers
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Massachusetts General Hospital
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Bristol-Myers Squibb | INDUSTRY |